Cargando…

Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring a PIK3CA Mutation

Metaplastic breast cancer (MpBC) is an extremely rare breast cancer subtype, characterized by a heterogeneous phenotype. MpBC aggressive biology is attributed to its stem cell-like characteristics. Since these tumors are largely chemoresistant, novel targeted therapies should be explored. Herein, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agarwal, Rishi, Koenig, Kimberly, Rohren, Eric, Subbiah, Vivek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197360/ https://www.ncbi.nlm.nih.gov/pubmed/25320628 http://dx.doi.org/10.4048/jbc.2014.17.3.287

Ejemplares similares

mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations
por: Wang, Zhiyong, et al.
Publicado: (2014)

Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity
por: Sterba, Martin, et al.
Publicado: (2023)

Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer
por: Yamaguchi, Hiroyuki, et al.
Publicado: (2015)

Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA
por: Garay, Joseph P., et al.
Publicado: (2021)

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
por: Coussy, F., et al.
Publicado: (2020)

Rheb and mammalian target of rapamycin in mitochondrial homoeostasis
por: Groenewoud, Marlous J., et al.
Publicado: (2013)

Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations
por: Ogasawara, Aiko, et al.
Publicado: (2020)

Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
por: Rugo, Hope S., et al.
Publicado: (2023)

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2011)

SIRT1 Negatively Regulates the Mammalian Target of Rapamycin
por: Ghosh, Hiyaa Singhee, et al.
Publicado: (2010)

Mammalian target of rapamycin signaling in diabetic cardiovascular disease
por: Chong, Zhao Zhong, et al.
Publicado: (2012)

Driving neural regeneration through the mammalian target of rapamycin
por: Maiese, Kenneth
Publicado: (2014)

Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin
por: Khadir, Fatemeh, et al.
Publicado: (2018)

Autism Spectrum Disorder and Mammalian Target of Rapamycin System
por: Posar, Annio, et al.
Publicado: (2020)

Crosstalk of the Caspase Family and Mammalian Target of Rapamycin Signaling
por: Yan, Junfang, et al.
Publicado: (2021)

Response to Mammalian Target of Rapamycin–Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation
por: Cuglievan, Branko, et al.
Publicado: (2018)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
por: Chandran, Smita S., et al.
Publicado: (2022)

Mutations of PIK3CA in gastric adenocarcinoma
por: Li, Vivian Sze Wing, et al.
Publicado: (2005)

Mutations in PIK3CA are infrequent in neuroblastoma
por: Dam, Vincent, et al.
Publicado: (2006)

PIK3CA-mutations in breast cancer
por: Reinhardt, Kristin, et al.
Publicado: (2022)

Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer
por: Xu, Da-zhi, et al.
Publicado: (2010)

Inhibition of mammalian target of rapamycin by rapamycin increases the radiosensitivity of esophageal carcinoma Eca109 cells
por: ZHANG, DEJUN, et al.
Publicado: (2014)

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin
por: Cufí, Sílvia, et al.
Publicado: (2013)

Mammalian target of rapamycin and head and neck squamous cell carcinoma
por: Liao, Yu-Min, et al.
Publicado: (2011)

Mammalian Target of Rapamycin: Hitting the Bull's-Eye for Neurological Disorders
por: Chong, Zhao Zhong, et al.
Publicado: (2010)

New Developments in Mammalian Target of Rapamycin Inhibitors for the Treatment of Sarcoma
por: Agulnik, Mark
Publicado: (2012)

Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2013)

The cytotoxic T cell proteome and its shaping by mammalian Target of Rapamycin
por: Hukelmann, Jens L., et al.
Publicado: (2015)

The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling
por: Yoon, Mee-Sup
Publicado: (2017)

The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
por: Lawrence, Jessica, et al.
Publicado: (2018)

Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation
por: Leal, Rita, et al.
Publicado: (2017)

Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
por: Querfurth, Henry, et al.
Publicado: (2021)

Mammalian Tribbles Homologs at the Crossroads of Endoplasmic Reticulum Stress and Mammalian Target of Rapamycin Pathways
por: Cunard, Robyn
Publicado: (2013)

PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
por: Payne, S N, et al.
Publicado: (2015)

Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer
por: Cardinali, Barbara, et al.
Publicado: (2022)

Targeting p85β nuclear translocation for the tumors with PIK3CA helical domain mutations
por: He, Baoyu, et al.
Publicado: (2022)

Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma
por: Jin, Hong-Guang, et al.
Publicado: (2018)

Rapamycin protects against aristolochic acid nephropathy in mice by potentiating mammalian target of rapamycin-mediated autophagy
por: Lin, Fan, et al.
Publicado: (2021)

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
por: Chan, S
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_kdderb5116vkipvrqed50olhuu